Clinical Trials on High-Risk Non-Muscle-Invasive Bladder Cancer

Total 830 results

C2i Genomics
Fox Chase Cancer Center; Baylor College of Medicine; New York University; The Cleveland... and other collaborators

Terminated

Clinical Performance Evaluation of the C2i-Test

Muscle-Invasive Bladder Carcinoma

United States
University of Florence
Azienda Ospedaliero-Universitaria Careggi

Recruiting

Robotic Radical Cystectomy Outcomes

Recurrence | Surgery | Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Oncology

Italy
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

NMIBC

China
ImmunityBio, Inc.

Withdrawn

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

NMIBC
Yuanquan Yang
Gateway for Cancer Research

Recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
Sandy Srinivas
GlaxoSmithKline

Completed

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Bladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer | Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

United States
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Completed

A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI (VI-RADS)

Muscle Invasive Bladder Cancer

Italy
Zhujiang Hospital

Recruiting

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

China
Shenyang Sunshine Pharmaceutical Co., LTD.
Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.

Not yet recruiting

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

NMIBC
Janssen Research & Development, LLC

Recruiting

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States (Nova-sTAR)

Non-Muscle Invasive Bladder Neoplasms

United States
Ding-Wei Ye

Completed

A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (VG-INFUSE Tria)

NMIBC

China
Memorial Sloan Kettering Cancer Center

Completed

A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing

Cancer Survivors | Statin Use Among High Risk Survivors

United States
Yung NA
Queen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital

Recruiting

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Muscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial Carcinoma

Hong Kong
Mansoura University

Unknown

Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy

Bladder Cancer | Infection | Complication | Oncology | Radical Cystectomy | Muscle Invasive

Egypt
Noah Hahn, M.D.
AstraZeneca; Hoosier Cancer Research Network

Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (ADAPT-BLADDER)

Bladder Cancer | Urothelial Carcinoma

United States
S. Andrea Hospital

Active, not recruiting

CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC (CRUCIAL-R)

Bladder Cancer Recurrence | Recurrence Free Survival

Italy
Matthew Galsky
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab in Muscle-invasive Bladder Cancer

Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Localized Cancer

United States
Columbia University
Regeneron Pharmaceuticals

Recruiting

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) (NeoSTOP-IT)

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

United States
Cairo University

Recruiting

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

Muscle-Invasive Bladder Carcinoma

Egypt
UNC Lineberger Comprehensive Cancer Center

Completed

ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Hopital Foch

Recruiting

Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers (TARDITEP)

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

France
H. Lee Moffitt Cancer Center and Research Institute
CG Oncology, Inc.; Richard M. Shulze Family Foundation

Completed

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Multi-parametric MRI in Patients of Bladder Cancer

Artificial Intelligence | Muscle-invasive Bladder Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Peking University First Hospital; China-Japan Friendship Hospital

Recruiting

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Muscle-invasive Bladder Cancer | Upper Tract Urinary Carcinoma

China
National Cancer Institute (NCI)

Completed

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Urinary Bladder Neoplasms

United States
Ain Shams University

Completed

Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection

Hypertonic Saline | Distilled Water | Irrigation | Normal Saline | Bladder (Urothelial, Transitional Cell) Cancer | Nonmuscle Invasive Bladder Cancer

Egypt
NYU Langone Health
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder

Muscle-invasive Urothelial Cancer of the Bladder

United States
Radboud University Medical Center

Not yet recruiting

Prospective Prostate Cancer Infrastructure (ProPCI)

High Risk Localized Prostate Cancer | Synchronous Metastatic Hormone-Sensitive Prostate Cancer
Flatiron Health

Recruiting

Pan-tumor MRD Study

Esophageal Cancer | Melanoma (Skin Cancer) | NSCLC (Non-small Cell Lung Cancer) | Muscle Invasive Bladder Urothelial Carcinoma | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Pancreatic (Exocrine Only) | Mix of Solid Tumors (MOST)

United States
Peter Black
University of British Columbia; Canadian Institutes of Health Research (CIHR)

Recruiting

NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment (NEO-BLAST)

Muscle-Invasive Bladder Carcinoma

Canada
Istanbul Medeniyet University

Recruiting

The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Bladder Cancer Recurrent | Non-Invasive Bladder Urothelial Carcinoma

Turkey
Leslie Ballas

Recruiting

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Muscle-Invasive Bladder Carcinoma | Tumor

United States
Oslo University Hospital
The Research Council of Norway; Haukeland University Hospital; St. Olavs Hospital and other collaborators

Active, not recruiting

BladMetrix Urine Test for Monitoring Recurrence in Non-Muscle Invasive Bladder Cancer (BladMetrix)

Urinary Bladder Neoplasms | Non-Muscle Invasive Bladder Neoplasms | Carcinoma, Transitional Cell, Bladder

Norway
Chinese PLA General Hospital
Beijing GeneX Health Technology Co., Ltd

Recruiting

Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection

Muscle-Invasive Bladder Carcinoma

China
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Relmada Therapeutics, Inc.

Withdrawn

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy (RESCUE)

Urothelial Carcinoma Bladder | Urologic Cancer | Urothelial Carcinoma Recurrent | Bladder (Urothelial, Transitional Cell) Cancer | Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Queen's University
Queen's University, Kingston, Ontario

Not yet recruiting

A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. (BCG-TIME)

Urothelial Carcinoma Bladder | NMIBC | Non-Muscle Invasive Bladder Urothelial Carcinoma | Bladder (Urothelial, Transitional Cell) Cancer

Canada
Cairo University

Unknown

Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer

Urothelial Carcinoma Bladder | High-Risk Cancer

Egypt
Chengdu CoenBiotech Co., Ltd
Hunan Cancer Hospital

Completed

Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)

Non-muscular Invasive Bladder Cancer

China
Regina Elena Cancer Institute

Active, not recruiting

Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt

Surgery | Chemotherapy Effect | Muscle-Invasive Bladder Carcinoma

Italy
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Non-Muscle Invasive Bladder Neoplasms
BLAD-HYA Group
Eulji University

Recruiting

Early vs Delayed Intravesical Blad-Care During BCG Therapy (PRO-GAG)

Urinary Bladder Neoplasms | BCG-Induced Cystitis

South Korea
Academisch Medisch Centrum - Universiteit van Amsterdam...
Bristol-Myers Squibb

Recruiting

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (CRIMI)

Urinary Bladder Cancer | Invasive Bladder Cancer

Netherlands
Baylor College of Medicine
Pfizer

Terminated

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Bladder Cancer | Invasive Bladder Cancer | Metastatic Bladder Cancer

United States
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Carcinoma in Situ | Urinary Bladder Neoplasms | Non-Muscle Invasive Bladder Neoplasms

Argentina, United States, Australia, Netherlands, Spain, France, Greece, Hungary, Italy, Brazil, Canada, Chile, Colombia, Germany, Poland, Peru, United Kingdom, Denmark, Thailand
UNICANCER

Active, not recruiting

Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30) (Bladder-ART)

Patients With High-risk MIBC

France
European Institute of Oncology

Terminated

Fenretinide in Healthy Young Women at Genetic and Familial Risk

High-Risk Cancer

Italy

Clinical Trials on High-Risk Non-Muscle-Invasive Bladder Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations